OKYO Pharma 将来の成長

Future 基準チェック /06

現在、 OKYO Pharmaの成長と収益を予測するのに十分なアナリストの調査がありません。

主要情報

n/a

収益成長率

n/a

EPS成長率

Biotechs 収益成長	28.5%
収益成長率	n/a
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	24 Oct 2024

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

NasdaqCM:OKYO - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
3/31/2025	N/A	-15	N/A	N/A	1
3/31/2024	N/A	-17	-9	-9	N/A
3/31/2023	N/A	-13	-8	-8	N/A
12/31/2022	N/A	-11	-7	-7	N/A
9/30/2022	N/A	-7	-5	-5	N/A
6/30/2022	N/A	-6	-5	-5	N/A
3/31/2022	N/A	-5	-5	-5	N/A
12/31/2021	N/A	-5	-5	-5	N/A
9/30/2021	N/A	-5	-4	-4	N/A
6/30/2021	N/A	-4	-3	-3	N/A
3/31/2021	N/A	-3	-2	-2	N/A
12/31/2020	N/A	-2	-1	-1	N/A
9/30/2020	N/A	0	-1	-1	N/A
6/30/2020	N/A	-1	-1	-1	N/A
3/31/2020	N/A	-2	-1	-1	N/A
12/31/2019	N/A	-3	N/A	N/A	N/A
9/30/2019	N/A	-5	-2	-2	N/A
6/30/2019	N/A	-5	-2	-2	N/A
3/31/2019	N/A	-5	-2	-2	N/A
12/31/2018	N/A	-4	N/A	N/A	N/A
9/30/2018	N/A	-3	-2	-2	N/A
6/30/2018	N/A	-15	-2	-2	N/A
3/31/2018	N/A	-28	-2	-2	N/A
12/31/2017	N/A	-27	N/A	-1	N/A
9/30/2017	N/A	-26	N/A	-1	N/A
6/30/2017	N/A	-13	N/A	-1	N/A
3/31/2017	N/A	0	N/A	-1	N/A
12/31/2016	N/A	0	N/A	0	N/A
9/30/2016	N/A	-1	N/A	0	N/A
6/30/2016	N/A	-1	N/A	0	N/A
3/31/2016	N/A	-1	N/A	-1	N/A
9/30/2015	N/A	-1	N/A	-1	N/A
6/30/2015	N/A	-1	N/A	-1	N/A
3/31/2015	N/A	-1	N/A	-1	N/A
12/31/2014	N/A	-6	N/A	-2	N/A
9/30/2014	N/A	-4	N/A	-3	N/A
6/30/2014	N/A	-9	N/A	-3	N/A
3/31/2014	N/A	-14	N/A	-3	N/A

アナリストによる今後の成長予測

収入対貯蓄率: OKYOの予測収益成長が貯蓄率 ( 2.6% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: OKYOの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: OKYOの収益が今後 3 年間で大幅に増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: OKYOの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: OKYO来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: OKYOの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

OKYO Pharma 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Recent updates

OKYO Pharma Limited Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain

OKYO Pharma Limited Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain

OKYO Pharma Limited announced delayed 20-F filing

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101

Okyo Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain

OKYO Pharma Limited Announces Appointment of Scientific Advisory Board

OKYO Pharma Limited Reports Positive Safety and Efficacy Results in Its Phase 2, Randomized, Double-Masted, Placebo-Controlled Trial Evaluating the Safety and Efficacy of OK-101 Ophthalmic Solution in Patients with Dry Eye Disease

OKYO Pharma Limited has filed a Follow-on Equity Offering in the amount of $4 million.

Okyo Pharma Limited Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit

OKYO Pharma Limited, Annual General Meeting, Dec 14, 2023

OKYO Pharma Limited has completed a Follow-on Equity Offering in the amount of $1.6389 million.

Okyo Pharma Limited Announces Filing of an Investigational New Drug (Ind) Application for Ok-101 to Treat Neuropathic Corneal Pain

OKYO Pharma Limited Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease (DED)

OKYO Pharma Limited has completed a Follow-on Equity Offering in the amount of $4.000005 million.

OKYO Pharma Limited has completed a Follow-on Equity Offering in the amount of $4.000005 million.

Okyo Pharma Limited Completes Enrollment in Phase 2 Clinical Trial of Ok-101 to Treat Dry Eye Disease

OKYO Pharma Limited announced delayed 20-F filing

OKYO Pharma Limited Plans to Initiate Phase 2 Trial of Ok-101 in Neuropathic Corneal Pain

OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer, Effective September 1, 2023

New minor risk - Shareholder dilution

OKYO Pharma Limited Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular Ok-101 for Dry Eye Disease

OKYO Pharma's Ordinary Shares of No Par Value, Fully Paid Cancels from Admission to Trading on London Stock Exchange

OKYO Pharma Announces Change of Delisting Date to 22 May 2023

OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease

OKYO Pharma Limited Announces U.S. IND Filing on Ok-101 for the Treatment of Dry Eye Disease

OKYO Pharma Plans Fourth Quarter 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm

OKYO Pharma Limited, Annual General Meeting, Sep 07, 2022

OKYO Pharma Limited announced delayed 20-F filing

OKYO Pharma Limited Announces Successful Completion of A Pre-IND Meeting with the U.S. Food and Drug Administration on the Development of OK-101 to Treat Dry Eye Disease

OKYO Pharma Limited Announces First-in-Class Drug Candidate OK-101 Displaying Both Anti-inflammatory and Ocular Pain-Reducing Potential to Treat Dry Eye Disease

OKYO Pharma Announces Positive Data and Results in an Animal Model Using Topically Administered OK-201 to Treat Neuropathic Ocular Pain

OKYO Pharma Limited Has U.S. Patent Issues Covering its Lipid Conjugated Peptide Analogues for Treating Ocular Pain and Inflammation

Okyo Pharma Limited Announces Filing of A Patent Application Covering the Use of Chemerin and Associated Analogues to Treat “Cytokine Storm” Associated with COVID-19 and ARDS

OKYO Pharma Limited Appoints Gary S. Jacob as Chief Executive Officer

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘